SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia shares are under pressure as traders react to the boards investigation into Jensen Huangs admitted affair with a businesswoman reported to have suspected ties to Chinese intelligence, raising concerns about governance, possible information leaks, and Huangs future as CEO. The community is divided between seeing the probe and leadership uncertainty as a serious overhang and treating the controversy as unrelated to Nvidias AI-chip business and a buying opportunity.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is under heavy selling pressure ahead of its Q3 earnings report, with traders speculating about a possible leak while others see the decline as pre-report positioning; a leak is unconfirmed. Bulls point to growth and potential upbeat guidance, while bears worry that the Eli Lilly obesity-drug deal could pressure margins and profitability.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

IWMs sharp rally is drawing attention as small caps outperform, with traders describing a possible low-volume short squeeze and rotation into the Russell 2000. Bulls are chasing calls and citing hopes for easing inflation, while skeptics question the moves strength given reported weak flows and limited volume.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics quarterly revenue beat and higher full-year outlook, driven by BRIUMVI growth, are the main focus; shares saw a sharp post-results dip and recovery, prompting debate over a sell the news reaction versus short-driven volatility. Traders are also watching for Phase 3 results on subcutaneous BRIUMVI as a next potential catalyst.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs rally is drawing attention after Oppenheimer upgraded the stock, while Google Clouds use of EPYC processors in its AI infrastructure added a company-specific catalyst. Traders also point to money rotating from Nvidia amid a CEO-related investigation, though some see the move as sentiment-driven and question AMDs valuation.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk shares are rallying sharply ahead of its Q3 earnings report, with traders speculating about short covering and an earnings leak, though neither explanation is confirmed. The move has fueled hopes for a turnaround, while many investors worry that weak results or guidance could erase the gains.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

A quarterly earnings shortfall and reduced full-year revenue guidance, tied largely to federal Dedrone drone deployments being delayed, have driven a sharp selloff. Traders debate whether the decline overreacts to a timing issue or reflects high valuation and weaker near-term growth, with some buying the dip and others expecting further downside.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Agility Robotics Inc.

Agility Robotics Inc. - Ordinary Shares - Class A

Post-merger selling in Agility Robotics is drawing attention, with traders pointing to typical de-SPAC volatility and questioning the companys steep losses, limited revenue, and path to commercial scale. Some remain bullish on humanoid robotics and the companys reported orders, but the discussion is dominated by skepticism about valuation and near-term execution.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors pending FDA decision on deramiocel for Duchenne muscular dystrophy, focused on the amended upper-limb-function evidence from HOPE-3, is driving attention ahead of the Nov. 22 PDUFA date. Bulls cite the trial data and a letter urging approval from 28 investigators, while skeptics point to FDA scrutiny and the earlier negative advisory-panel vote on the cardiac indication; short-squeeze speculation adds to the debate.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

SITC data from Candels PrTK05 prostate-cancer study, highlighting systemic immune activation and transient vector clearance, has renewed attention on the planned CAN-2409 BLA submission, following positive Phase 3 results. Bulls view the findings as supportive of the regulatory package, while skeptics question whether the biomarker data materially reduce BLA risk and remain concerned about timing, CEO transparency and possible dilution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ansys, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - ANSS

Ansys, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - ANSS Ansys, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your...

ANSS Investors Have Opportunity to Join Ansys, Inc. Fraud Investigation with the Schall Law Firm

ANSS Investors Have Opportunity to Join Ansys, Inc. Fraud Investigation with the Schall Law Firm ANSS Investors Have Opportunity to Join Ansys, Inc. Fraud Investigation with the Schall Law Firm PR...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ansys, Inc. (Ansys or the Company) (NASDAQ: ANSS) for...

The Trade Desk Stock Climbs Higher on S&P 500 Debut as ANSYS Drops Out

TTD jumps 6.6% as it joins the S&P 500. The company expects CTV growth, Kokai demand and global ad trends to fuel momentum.

Ansys Acquisition by Synopsys Clears Regulatory Hurdles Worldwide

ANSS moves closer to merging with Synopsys as final global approvals secure $35B deal set to close July 17.

Ansys (ANSS) Moves 3.0% Higher: Will This Strength Last?

Ansys (ANSS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Synopsys-Ansys’ $35B Deal Reportedly Gets China’s Conditional Approval Days Before Closure Deadline

Equity

China’s approval removes the final global barrier for the deal, with conditions ensuring continued design tool access for Chinese customers and partners.

China approves Synopsys’ $35 bln Ansys acquisition

Investing.com-- China’s market regulator has provided conditional approval to Synopsys (NASDAQ:SNPS) for its $35 billion acquisition of Ansys (NASDAQ:ANSS), clearing a key regulatory hurdle for the U.S. chip-design software giant

ANSS Simulation Solutions Used by Wingcopter to Boost  Drone Designs

ANSS, Turbotech Team Up to Fuel a Hydrogen-Powered Future in Aviation

ANSYS, Inc. engages in the development and marketing of engineering simulation software and services. The firm's solutions include automotive, aerospace and defense, construction, energy, materials and chemical processing, autonomous engineering, and electrification. The company was founded by John A. Swanson in 1970 and is headquartered in Canonsburg, PA.

Ansys Inc. - Registered Shares

Neutral Sentiment

China's antitrust authority has greenlit Synopsys Inc.(SNPS)'s $35 billion acquisition of engineering software firm Ansys Inc. (ANSS), clearing the final international hurdle for the deal between two key players in&nbsp;the electronic design automation (EDA)&nbsp;industry.According to a Reuters&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/world/china/china-grants-conditional-approval-synopsys-acquire-ansys-2025-07-14/">report</a>, the conditional approval from the State Administration for Market Regulation (SAMR) came just days ahead of the deal’s July 15 closure deadline.&nbsp;Following the news,&nbsp;<a href="https://stocktwits.com/symbol/SNPS">Synopsys stock</a> traded 3.3% higher in Monday’s premarket session.While regulatory bodies in other key global markets had already approved the transaction, doubts lingered over whether Chinese authorities would delay the deal due to ongoing political and trade friction.&nbsp;Investor anxiety grew after the United States imposed limits on the export of specific semiconductor design technologies to China, prompting speculation that Beijing might respond with its countermeasures.Synopsys had&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/synopsys-restarts-partial-services-in-china-amid-us-export-curbs/chlXDS8Rb6s">suspended</a> its services in China in June after U.S. export controls compelled the company to stop sales and support operations. It also&nbsp;paused its financial forecasts for both the third quarter and the fiscal year 2025.&nbsp;The approval arrives just weeks after President Donald Trump’s administration lifted restrictions on exports of critical semiconductor design tools to China.The ban, introduced in May, had impacted not only Chinese customers but also employees of foreign firms operating within China. Its lifting paved the way for the long-pending deal to resume progress, stated a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.scmp.com/tech/big-tech/article/3318140/tech-war-china-approves-synopsys-acquisition-ansys-after-us-lifts-eda-ban?module=perpetual_scroll_0&amp;pgtype=article">report</a> from SCMP.&nbsp;China's approval was granted under a set of obligations. The merged company is expected to provide Chinese customers with continued, unbiased access to electronic design automation tools.&nbsp;Additionally, the firms must honor all existing agreements, renew interoperability partnerships upon request, and preserve their current contractual commitments in the Chinese market.The deal is expected to bolster Synopsys’ position against rival Cadence, broadening its product suite and deepening its foothold in the EDA sector.&nbsp;On Stocktwits, retail sentiment toward Synopsys shifted to ‘neutral’ from ‘bearish’&nbsp; territory the previous day amid ‘low’ message volume levels.<figure class="image"><img style="aspect-ratio:807/104;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_14_at_7_27_58_AM_png_9595235e95.webp" alt="SNPS’s Sentiment Meter and Message Volume as of 07:30 a.m. ET on July 14, 2025 | Source: Stocktwits" width="807" height="104"><figcaption>SNPS’s Sentiment Meter and Message Volume as of 07:30 a.m. ET on July 14, 2025 | Source: Stocktwits</figcaption></figure>Synopsys stock has gained over 15% year-to-date and has lost over 9% in the last 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alphabet-reportedly-strikes-2.4-b-licensing-deal-with-with-windsurf/ch8BFF2R5Vb">Alphabet Reportedly Strikes $2.4B Licensing Deal With Windsurf, Snags Founders And AI Researchers After OpenAI's Failed Bid</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Synopsys logo is seen displayed on a smartphone with the flag of China in the background. 

Leverage Shares 1x Short Anthropic Daily ETF

Synopsys Inc

Vanguard S&P 500 ETF

Vanguard Total Stock Market ETF

Buying the dip

Selling or trimming

Holding

Waiting for the investigation results to decide

Nvidia ($NVDA) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Stocktwits

) is down about 4% after its board opened an investigation into CEO Jensen Huang. What are you doing with the stock?

Feed

News

Sentiment

Fundamentals

Info

ANSS Leverage Shares 1x Short Anthropic Daily ETF

Latest ANSS News